North America Metaxalone Market

The size of the North America Metaxalone Market is forecasted to grow at a prominent rate during the forecast period.

The increasing number of musculoskeletal disorders and rheumatoid arthritis are the two primary factors expected to drive the North American metaxalone market. Also, the rising number of athlete gym establishments and the rising prevalence of sports injuries further boost the market growth. In addition, the Y-O-Y rise in the number of road accidents significantly influences the demand for the market. Every year, about 1.25 million people are killed in car accidents, an average of 3,287 deaths each day. In addition, about 37,000 people are killed in car accidents in the United States, and 2.35 million are injured or disabled every year. Road accidents cost the United States $230.6 billion per year or $820 per person.

On the other hand, the growing geriatric population significantly enhances the metaxalone market because the senior population is more susceptible to musculoskeletal disorders such as joint, bone, and other muscle problems. In addition, the technological advancements and innovations in product development are most likely to fuel market growth. Moreover, the progress in the pharmaceutical industries in emerging countries such as U.S. and Canada are projected to provide lucrative growth opportunities to the market growth. 

The key market players are focused on new product launches to gain the market's competitive advantage. Also, the strategies such as mergers, acquisitions, and partnerships strengthen the regional market growth. 

However, the side effects associated with the metaxalone usage, such as headache, vomiting, irritability, and nausea, hinder the metaxalone market growth in the North American region. 

This research report on the North American metaxalone market has been segmented and sub-segmented into the following categories.

By Indication:

• Bone Pain
• Muscle Pain            
• Tunnel Syndrome
• Joint Pain 
• Others     

By End User:

• Hospitals
• Clinics
• Others

By Country:

• The United States
• Canada
• Rest of North America

Geographically, North America recorded the largest share of the global market in 2020, and it is projected to witness a significant share during the forecast period. The increasing number of musculoskeletal conditions, development of pharmaceutical industries, and high healthcare spending are fuelling the market growth. In addition, the presence of key market players, market strategies, and supportive government policies are contributing to the market growth. Furthermore, the World Health Organization's and local governments' strengthening of drug prescription laws has created enormous market prospects for metaxalone in the region.

The USA holds a significant share in the market due to the presence of market leaders and the presence of a stellar healthcare system. In addition, the USA is also the fastest-growing region due to increasing disposable income, growing awareness, and increasing adoption rate.

The Canadian market is most likely to represent a promising share in the North American metaxalone market during the forecast period. The growing number of incidents resulted in injuries, growing awareness among the people, and new product launches boosted the market growth. 

KEY MARKET PLAYERS:

Some of the key players dominating this market include Biosynth, Chunghwa Chemical Synthesis and Biotech, Sigma Aldrich, CDI Technology, Angelini, Pfizer, Aurum Pharmatech, Finetech Industry Limited, Biochem, and Oxchem Corporation.